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Abstract 
 
Background: Since the time when drugs began to be used, it became evident that they could produce a therapeutic effect, 
but also a clinical condition of toxicity or no effect at all on humans, despite using the same doses in different patients. 
Such untoward effects were termed “drug idiosyncrasy” and also “idiosyncratic drug effects”, but the factors producing 
such diverse responses were never taken into account.     
Materials and Methods: Ruta chalepensis L. (fringed rue) is an herbaceous plant of the Rutaceae family used in 
traditional medicine due to its properties, such as its analgesic and antipyretic effects. This study used 25 male rats divided 
into five groups. Plant extract was administered to Groups 1 and 2 at doses of 100 and 30 mg/kg/day, respectively, for three 
days; Group 3 was administered 100 mg/kg/day of dexamethasone (DEX), as well as 100 mg/kg/day of Ruta chalepensis 
extract; Group 4 was administered 100 mg/kg/day of DEX and treated as positive control; Group 5 was treated as negative 
control and was administered a physiological solution.   Twenty-four hours after the the last dose, the animals were 
sacrificed and their livers were extracted. 
Results: The aqueous extract of Ruta chalepensis, intraperitoneally administered, was able to induce cytochrome 3A1 in 
doses of 30 mg/kg/day, and a greater inducing effect occurs when the plant is co-administered in doses of 100 mg/kg/day 
with dexamethasone. 
Conclusion: This study suggests that aqueous extract of Ruta chalepensis can induce cytochrome 3a1. This study helps 
provide a better understanding of CYP3a regulation. Future in vitro work is needed to determine the compounds that 
produce the cytochrome modulation. 
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Introduction 
 
Cytochrome P450 (CYP450) enzymes belong to a superfamily of hemoproteins that play an important role in the 
metabolism of endogenous as well as exogenous compounds, such as drugs of clinical importance, carcinogens, steroids, 
and cholesterol (Liu, 2010; Sarkar et al., 2003). These enzymes are also charged with metabolizing thousands of bioactive 
compounds of plants with very diverse chemical structures (Laursen et al., 2011). These enzymes are the main mechanism 
for increased, diminished, or null bioavailability of herbal-based drugs and compounds when said enzymes and drugs are 
simultaneously administered (Pekthong et al., 2009; Wang et al., 2009). They are termed P450 because an absorbance peak 
is produced at 450 nm when treated with a reducer agent and linked with carbon monoxide (Pan et al., 2011). In rats, the 
CYP450 enzymes commonly involved in the metabolism of xenobiotics include CYP1a2, CYP2c11, CYP2e1, and 
CYP3a1/2 (Li et al., 2008), while in humans, the enzymes involved are CYP1A2, CYP2C9, CYP2D6, and CYP3A4 
(Ponnusankar et al., 2011; Zhou et al., 2011). The overexpression of CYP3A4 has been reported to contribute to the 
development of leukemia, prostate cancer, and breast cancer (Keshava et al., 2004). A decrease in CYP3A4 overexpression 
appears to reduce the risk of cancer in children (Swinney et al., 2006). In rats, the CYP3A subfamily is the second in 
importance, followed by Cytochrome 2C11, with an abundance of 39%; however, the CYP3A subfamily is responsible for 
metabolizing 50–60% of all currently employed drugs: it is thus the most important and abundant enzyme in the human 
organism (Dally et al., 2003; Zhou et al., 2007). CYP3A is expressed mostly in the liver and the gastrointestinal tract (Chen 
et al., 2009). People tend to combine different plant preparations with modern prescription drugs, in that they consider it 
safe to consume herbal derivatives; such combinations can produce plant-drug interactions (Pekthong et al., 2009). Ruta 
chalepensis (R. chalepensis) is native to southern Europe and the Eastern Mediterranean region, where it is known as Ruda; 
this plant is cultivated in the greater part of the American continent. By virtue of its analgesic and antipyretic effects, it has 
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been used in the treatment of neuralgia, rheumatism, and menstrual disorders (al-Said et al., 1990), as an abortive and 
antirheumatic, for intestinal and hepatic diseases, as an antiepileptic and antipyretic, it is also useful in perfumery, and it has 
insecticidal activity (Pino et al., 2014; Di Stasi et al., 1994). Phytochemical screening of R. chalepensis has shown the 
presence of campherol, rutin, quercetin, bergapten, chalepsin, psoralen, skimmianine, kokusaginine, graveoline, 
furoquinoline, γ-fagarine, dictamnine, arborinine, and chalepensin (Schmelzer and Gurib-Fakim, 2013), as well as 
coumarins, which are employed in the treatment of the symptoms of multiple sclerosis (Orlita et al., 2008). Flavonoids, 
glycosides, and tannins are considered potent pro-inflammatory molecule inhibitors. In this study, we employed the 
aqueous-type R. chalepensis extract used by popular medicine in the form of an infusion and/or decoction from the plant 
(Khadhri et al., 2017). 
 
Materials and Methods 
Preparation of the aqueous extract of R. chalepensis 
 
Five kg of fresh R. chalepensis plant specimens were acquired in the North of Mexico (25.53607 N, 103.52117 
W). The plant material was dried for 10 days at room temperature. The aerial parts were ground to a fine powder. One 
hundred g of fresh powder was weighed, and 1,000 mL of distilled water was added; the mixture was heated to 100º C, 
shaken for 1 h, and then filtered with Whatman Nº 1 filter paper using a vacuum pump. The filtrate was taken to dryness in 
a furnace set at 40ºC to obtain the dry extract, which was stored at 5ºC in the dark until it was used. A voucher specimen of 
Ruta chalepensis, numbered 60663, was deposited in the Herbarium of the Benemérita Universidad Autónoma de Puebla 
(BUAP), Mexico. 
 
In vivo study with Wistar rats 
 
We placed 25 male 11-week old Wistar rats in five cages, five animals per cage. The weights of the rats were 
between 250 and 300 g. For seven days prior to the treatment, the rats were maintained under standard laboratory 
conditions (temperature 24ºC, 12-h light/dark cycles, 45% relative humidity) with ad libitum access to pellets (Teklad® 
18% protein) and water. None of the animals was replaced during the study. The experimental protocol was approved by 
the Bioethics Committee of the Universidad Autónoma de Coahuila, Facultad de Medicina, in Mexico, with approval 
number 0100-10. The rats were treated via intraperitoneal (i.p.) injection with 100 and 30 mg/kg/day of R. chalepensis 
extract, respectively, for groups 1 and 2. Another group was administered 100 mg/kg/day of Dexamethasone (DEX) 
combined with 100 mg/kg/day of R. chalepensis extract. As a positive control, one group was administered 100 mg/kg/day 
of DEX. We employed saline solution (0.9%) as vehicle with all of the groups at a dose of 6.67 mL/kg/day, with the 
exception of the positive control group, which was administered corn oil (6.67 mL/kg/day) for 3 consecutive days. After the 
last administration session, all rats were fasted for 24 h, were then anesthetized with ether, sacrificed, and their livers were 
extracted; the liver tissues were placed in RNALater® until they were processed.  
 
Extraction of messenger RNA (mRNA) 
 
Livers were cut into 3-mm-thick slices, which were submerged in RNALater® (Qiagen®, USA); these samples 
were stored at 4ºC for 24 h for RNase inactivation, and were later frozen at –20ºC until they were processed. The mRNA 
was isolated utilizing the RNeasy Protect Mini Kit (Qiagen®, USA), following the manufacturer’s instructions. 
 
Real-time quantitative PCR, Reverse Transcription, and qPCR (qRT-PCR) 
 
We employed the primers 5´-TTCACCGTGATCCACAGCA-3´ and 3´-TGCTGCCTTGTTCTCCTT-5´ of 
CYP3a1; these were confirmed in GenBank with access number L24207; as control, we utilized GAPDH (Taqman® 
Rn01775763_g1) ((Morioka et al., 2006). 
For amplification, we used TaqMan® catheters with 50 denaturation cycles of 15 sec at 92ºC. Hybridization was 
carried out for 90 min at 60ºC. The qRT-PCR reaction was developed using Applied Biosystem 7300® equipment and the 
Techne® Thermocycler. 
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Toxicity test in microplates 
 
In order to calculate the median Lethal Dose (LD50), we employed the Artemia salina larval bioassay (San 
Francisco Bay Brand Brine Shrimp Eggs®); we placed 20g of cysts in 500 mL of Instant Ocean® Sea Salt, and the pH value 
was adjusted to 7.8 for cyst incubation at a temperature of 22–25°C for 48 h under a white light lamp. After this, we 
prepared dilutions of 50, 125, 250, 750, and 1,000 ppm. We inserted 10 nauplii per well, and 24 h later, we counted the 
dead and live nauplii. In the toxicity bioassay, larvae were considered dead when no movement was observed after 
observation for a number of seconds (Carballo et al., 2002). The calculation of LD50 was obtained using Minitab software 
(v. 15.0 for Windows; State College, PA, USA). The toxicity criteria employed are in agreement with those utilized by 
Bastos et al. (2009) and Déciga-Campos et al. (2007), where LD50 values >1,000 µg/mL are non-toxic, values ≥500 and 
≤1,000 µg/mL have weak toxicity, and values <500 µg/mL are toxic. 
 
Statistical analysis 
 
Difference between groups was obtained using the non-parametric Mann–Whitney U analysis. The LD50 was 
determined by linear regression analysis using the SPSS Science statistical software (v. 15.0 for Windows; SPPS, Inc., 
Chicago, IL, USA), as well as GraphPad Prism (v. 5.0 for Windows; San Diego, Ca, USA), and Minitab (v. 15.0 for 
Windows; State College, PA, USA). The significance level was established at p <0.05.  
 
Results 
Effect of the treatment with aqueous extract of Ruta chalepensis on Wistar rats 
  
Body Weight (BW) was not affected by the treatment (data not shown). Tables 1 and 2 present the mRNA levels 
obtained from the treatment groups in comparison with the control group, which was treated with saline solution only. 
Treatment for 3 consecutive days with DEX (100 mg/kg/day) caused an inducer effect 9.94-fold that of cytochrome; in the 
treatment groups, the effect was inversely proportional to the concentration of the extract employed, producing a 0.93-fold 
decrease with regard to the control in the group in which Ruta chalepensis was administered at 100-mg/kg doses, and a 
2.06-fold enzymatic induction increase in the group that was administered 30-mg/kg doses of aqueous extract. In the third 
group (R. chalepensis plus DEX, both at 100-mg/kg/day doses), there was a 5.84-fold increase in comparison with the 
saline solution group (Figure 1; Figure 2). 
 
Table 1: Fold change of messenger RNA (mRNA) as a result of intraperitoneal (i.p.) administration of aqueous extract of 
Ruta chalepensis for 3 consecutive days (n = 25)a. 
 
Treatment Times of change 95% CI P 
Saline solution 
(6.67mL/kg/day) 
1.643 ± 1.034 0.358 ± 2.928  
Dexamethasone (100 
mg/kg/day) 
 
9.949 ± 2.599 
 
6.722 ± 13.18 
 
 
0.008* 
R. chalepensis 
(100 mg/Kg/day) 
 
0.715 ± 0.843 
 
-0.332 ± 1.763 
 
0.310 
R. chalepensis 
(30 mg/Kg/day) 
 
3.702 ± 1.432 
 
1.923 ± 5.480 
 
0.032* 
& Dexamethasone and  
R. chalepensis 
 
7.486 ± 2.538 
 
4.335 ± 10.64 
 
0.008* 
a Results are expressed as mean ± Standard Deviation (SD). * Mann–Whitney U test (p <0.05), with respect to the saline 
solution. &R. chalepensis plus DEX, both at 100-mg/kg/day doses. 
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Table 2: Quantification of mRNA levels in Wistar rat liver as a result of intraperitoneal (i.p.) administration of aqueous 
extract of Ruta chalepensis for 3 consecutive days (n = 25)a 
 
Treatment Media ± DE (µL/ng) 
Saline solution (6.67mL/kg/day) 29 ± 1.6* 
Dexamethasone  
(100 mg/kg/day) 
23 ± 2.0* 
R. chalepensis 
(100 mg/Kg/day) 
 
26 ± 1.0 
R. chalepensis 
(30 mg/Kg/day) 
 
25 ± 2.1* 
& Dexamethasone and  
R. chalepensis 
 
20 ± 1.2* 
 
 
a Results are expressed as mean ± Standard Deviation (SD). Post Hoc Tukey (p<0.05), with respect to the saline solution. 
&R. chalepensis plus DEX, both at 100-mg/kg/day doses.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effect of the aqueous extract of Ruta chalepensis on the expression of messenger RNA (mRNA) of CYP3a1 in 
Wistar rat (n = 25) after 72h of treatment. Results aree expressed as the number of times of change compared with the 
control group (n=5), which was administered saline solution. Interaction: Ruta chalepensis (100 mg/kg/day) plus 
Dexamethasone (DEX) (100 mg/kg/day). 
 
 
Figure 2: Real-time PCR amplification plot. 
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Toxicity Test on Microplate 
 
There was a dose-response relationship reflected by a linear regression graph (Figure 3); the median Lethal Dose 
(LD50) calculated was 109.93 µg/mL. 
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Figure 3: Transformation of the percentage of mortality of Artemia salina for the aqueous extract of Ruta chalepensis. 
Each point represents the mean of three repetitions per dose. The median Lethal Dose (LD50) calculated was 109.93 µg/mL.  
 
Discussion 
 
The drug-plant interactions produced by cytochrome P450 (CYP450) have been widely studied; thus, these 
interactions could attain clinical significance. In view of the toxicity evaluation results obtained by the Artemia salina 
assay, the aqueous extract of R. chalepensis was found to be toxic. This result coincides with other reports indicating that 
methanolic and aqueous extracts of Ruta graveolens are toxic at LD50 values <100 µg/mL (Serrano-Gallardo, 2005). The 
present study evinced the capacity of the aqueous extract of R. chalepensis in modulating the expression of mRNA of 
CYP450. In 2005, de Freitas et al. evaluated the effect of R. graveolens methanolic extract for 15 days via oral route in 
1,000-mg/kg doses in mice, concluding that this plant can damage diverse organs; therefore, R. graveolens should not be 
employed as a medicinal plant. On the other hand, Lee et al. (2011) conducted a study on the use of tanshinones against 
cancer via chemoembolization. Thus, it is important to know the type of cytochrome modulation via injectable extract 
route.  
This study was focused on CYP3a, one of the main enzymes in the metabolization process of currently produced 
drugs (Mrozikiewicz et al., 2010). Previous research has reported on the assessment of different solvents used to obtain R. 
chalepensis extract; its authors have concluded that the aqueous extract contains the greatest amount of constituents and 
cancels the risk of ethanol, hexane, or another type of solvents interacting with the plant’s constituents, which cause an 
effect on the cytochromes under study (Nazish et al., 2009). This is a possible explanation to the results found by Pan et al. 
(2011), who concluded that the petroleum ether (PE) extract of Orthosiphon stamineus produces the greatest inhibitor effect 
on CYP2C19. At the time this experiment was published, there were no other studies on R. chalepensis extract in 
cytochromes available to compare our results; however, previous research reports on the study of other plants, such as 
Andrographis paniculata (Pekthong et al., 2009), Orthosiphon stamineus, Aframomum cuspidatum (Agbonon et al., 2010), 
and Centella asiatica (Pan et al., 2011) in cell culture. Centella asiatica was also studied in vivo by Kulthong et al., (2009). 
the authors administered the extract orally for 90 days at doses of 1,000, 100, and 10 mg/kg/day; however, their study did 
not report that the extract produces a modulator effect. Some of the cytochromes studied so far include the following: 1A1 
(Kulthong et al., 2009; Álvarez-González et al., 2010); 1A2 and 2B1/2B2 (Pan et al., 2011; Kulthong et al., 2009); 2C9, 
2D6, and 3A4 (Ponnusankar, et al., 2011; Zhou et al., 2011). The DEX adminstered produced an increase in messenger 
RNA (mRNA) levels in CYP3a1; these results are in agreement with those presented by Pekthong et al. (2009), Wang & 
Yeung (2011), Lee et al. (2011), Cantiello et al. (2009), Ooi et al. (2011), and Kishida et al. (2008); moreover, Kishida et al 
(2008) demonstrated that DEX is a selective inducer of CYP3a1, and that this induction is favored in Wistar rats. One of 
the strengths of the present study is that all of the groups were maintained, and that the same administration route was 
employed (Badal et al., 2011; Kondo et al., 2011). 
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